# Q&A

# Q&A Session at the Financial Results Briefing for the Six Months Ended for the FYE March 2026

Date of Financial Results Briefing :
November 12, 2025

TSE Prime Market
Securities code：7600

| | |
|---|---|
| Q1 | Regarding the remaining supply chain risks in U.S. knee joint manufacturing, when do you anticipate the supply chain will normalize? |
| A | Currently, BKS Primary (first-time replacement product) and BKS Revision Knee (Replace Again product) face supply chain risks.<br>①BKS Primary Knee Joint<br>Regarding BKS Primary, improvements to manufacturing issues are progressing, and we expect to see a resolution within the year.<br>②Revision Knee product BKS Revision Knee<br>BKS Revision Knee continues to experience manufacturing issues within the supply chain. Based on current projections, we anticipate this situation will persist until the first quarter of 2026. This product has a high unit price and generates significant sales, so it has been reflected in the full-year sales forecast for the FYE ending March 2026. |
| Q2 | Could you share details about the new product scheduled for launch in the U.S. during the 2H, to the extent possible? |
| A | The new product scheduled for launch in the U.S. in the 2H will be in the Hip joint field. |

| Q3 | Please tell me about the impact on business due to the change to the Takaichi administration. |
| --- | --- |
| A | Prime Minister Sanae Takaichi stated in her policy address that "protecting the lives and health of the people is an important aspect of national security." At this time, we understand that there has been no direct impact on our business.<br>However, going forward, the government may announce its policy regarding medical expenses.<br>Depending on the content of this policy, it could lead to revisions in the insurance reimbursement prices for our products.<br>In such a case, it is anticipated that our business would experience a certain degree of impact. |